KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Opko Health (OPK) over the last 16 years, with Q3 2025 value amounting to $3.0 million.

  • Opko Health's Share-based Compensation rose 714.29% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 184.68%. This contributed to the annual value of $11.0 million for FY2024, which is 319.81% down from last year.
  • Opko Health's Share-based Compensation amounted to $3.0 million in Q3 2025, which was up 714.29% from $2.2 million recorded in Q2 2025.
  • Opko Health's 5-year Share-based Compensation high stood at $7.6 million for Q1 2022, and its period low was $2.2 million during Q2 2025.
  • Over the past 5 years, Opko Health's median Share-based Compensation value was $3.0 million (recorded in 2025), while the average stood at $3.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 18775.97% in 2022, then plummeted by 6432.98% in 2023.
  • Over the past 5 years, Opko Health's Share-based Compensation (Quarter) stood at $3.7 million in 2021, then fell by 13.75% to $3.2 million in 2022, then fell by 16.5% to $2.7 million in 2023, then grew by 14.29% to $3.0 million in 2024, then dropped by 1.57% to $3.0 million in 2025.
  • Its Share-based Compensation stands at $3.0 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.6 million for Q1 2025.